BRIEF-Psyence Biomedical Announces Closing Of Previously Announced Acquisition Of Psyence Group'S Stake In Psylabs-December 2024-www.financetom.com

BRIEF-Psyence Biomedical Announces Closing Of Previously Announced Acquisition Of Psyence Group'S Stake In Psylabs

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Psyence Biomedical Announces Closing Of Previously Announced Acquisition Of Psyence Group'S Stake In Psylabs

Nov 3, 2024 3:34 PM

Oct 31 (Reuters) - Psyence Biomedical Ltd ( PBM ):

* PSYENCE BIOMEDICAL ANNOUNCES CLOSING OF PREVIOUSLY

ANNOUNCED

ACQUISITION OF PSYENCE GROUP'S STAKE IN PSYLABS

Source text:

Further company coverage:

Previous page： Market Chatter: AstraZeneca's Former Executives Under Investigation in China Next page： IDEAYA Biosciences Reports 'Positive' Interim Phase 1 Data for Cancer Drug; Shares Rise Pre-Bell

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Market Chatter: AstraZeneca's Former Executives Under Investigation in China

Nov 3, 2024

08:08 AM EDT, 10/25/2024 (MT Newswires) -- AstraZeneca's ( AZN ) former senior executive is being investigated by Chinese authorities, Bloomberg reported on Friday, citing local media outlets. The report said Eva Yin, currently the Chief Commercial Officer for Beigene, was recently detained. It added that Yin had worked at AstraZeneca ( AZN ) for over 15 years, including serving...

IDEAYA Biosciences Reports 'Positive' Interim Phase 1 Data for Cancer Drug; Shares Rise Pre-Bell

Nov 3, 2024

08:06 AM EDT, 10/25/2024 (MT Newswires) -- IDEAYA Biosciences ( IDYA ) reported positive interim expansion data Friday for IDE397 in patients with methylthioadenosine phosphorylase-deletion urothelial cancer and non-small cell lung cancer. The oncology company said that it observed a manageable safety profile with no drug-related serious adverse events or discontinuations at the 30mg once-a-day expansion dose. Shares of IDEAYA...

New US tariffs could prompt Signify to move some production from China, CEO says

Nov 3, 2024

AMSTERDAM, Oct 25 (Reuters) - Lighting maker Signify is considering moving some of its production out of China if the company is confronted with a new round of U.S. tariffs, its chief executive said on Friday. Signify, the world's biggest maker of lights, is looking at production sites in India, Indonesia and changing existing operations in Mexico, CEO Eric Rondolat...

New US tariffs could prompt Signify to move some production from China, CEO says

Nov 3, 2024

AMSTERDAM (Reuters) - Lighting maker Signify is considering moving some of its production out of China if the company is confronted with a new round of U.S. tariffs, its chief executive said on Friday. Signify, the world's biggest maker of lights, is looking at production sites in India, Indonesia and changing existing operations in Mexico, CEO Eric Rondolat said on...